Natera’s flagship product, Signatera is a personalized MRD blood test that detects cancer recurrence by identifying the ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

One company has a big early lead in blood tests that detect cancer returning in survivors.

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

Learn more Marks the first Medicare coverage decision for Veracyte’s whole-genome sequencing-based TrueMRD platform and launch of the first test SOUTH SAN FRANCISCO, Calif., May 15, 2026--(BUSINESS ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

Molecular residual disease, or MRD, testing is emerging as a powerful tool in breast cancer, offering new visibility into what traditional imaging cannot detect. 1 MRD tests, like the Oncodetect® test ...

Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...

The FDA's Breakthrough Devices Program accelerates access to promising medical devices for serious conditions, ensuring safety and effectiveness through a rigorous review process. Haystack MRD test ...

Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers. Minimal residual disease, or MRD, ...

Minimal residual disease (MRD) testing is poised to transform cancer care, according to John Truesdell, Chief Business Officer at Foresight Diagnostics. In a recent interview with Fierce, Truesdell ...